CN107022548B - Anti- AQP4 autoantibody detection material of a kind of human body and preparation method thereof - Google Patents
Anti- AQP4 autoantibody detection material of a kind of human body and preparation method thereof Download PDFInfo
- Publication number
- CN107022548B CN107022548B CN201710175642.9A CN201710175642A CN107022548B CN 107022548 B CN107022548 B CN 107022548B CN 201710175642 A CN201710175642 A CN 201710175642A CN 107022548 B CN107022548 B CN 107022548B
- Authority
- CN
- China
- Prior art keywords
- aqp4
- cell
- pci
- neo
- hek293
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 54
- 239000000463 material Substances 0.000 title claims abstract description 50
- 102000012002 Aquaporin 4 Human genes 0.000 title claims abstract description 39
- 108010036280 Aquaporin 4 Proteins 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 70
- 210000000170 cell membrane Anatomy 0.000 claims abstract description 61
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 27
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 239000007788 liquid Substances 0.000 claims description 21
- 239000013612 plasmid Substances 0.000 claims description 19
- 239000012528 membrane Substances 0.000 claims description 15
- 101150073415 Aqp4 gene Proteins 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 229910000406 trisodium phosphate Inorganic materials 0.000 claims description 12
- 238000010790 dilution Methods 0.000 claims description 11
- 239000012895 dilution Substances 0.000 claims description 11
- 239000000819 hypertonic solution Substances 0.000 claims description 10
- 229940021223 hypertonic solution Drugs 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 239000012071 phase Substances 0.000 claims description 9
- 230000001376 precipitating effect Effects 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 210000000172 cytosol Anatomy 0.000 claims description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000003599 detergent Substances 0.000 claims description 6
- 239000007791 liquid phase Substances 0.000 claims description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 108091008146 restriction endonucleases Proteins 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- 229920002866 paraformaldehyde Polymers 0.000 claims description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims description 3
- 239000004677 Nylon Substances 0.000 claims description 3
- 229920004890 Triton X-100 Polymers 0.000 claims description 3
- 239000013504 Triton X-100 Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 239000012096 transfection reagent Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 238000003151 transfection method Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 abstract description 12
- 238000010166 immunofluorescence Methods 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 210000002966 serum Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 230000029087 digestion Effects 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000004140 cleaning Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 102000010637 Aquaporins Human genes 0.000 description 2
- 108010063290 Aquaporins Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 101000942941 Arabidopsis thaliana DNA ligase 6 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000010454 slate Substances 0.000 description 1
- -1 slightly dry Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides anti-AQP4 autoantibody detection materials of a kind of human body and preparation method thereof, first obtain the AQP4 overall length target gene of M1, M23 hypotype, it is contaminated in HEK293 cell, constructs the HEK293/pCI-neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell of expression M1, M23 hypotype AQP4；The AQP4- cell membrane complexes in above-mentioned cell are extracted again；Finally AQP4- cell membrane complexes are solidificated on carrier and detect material to get to the anti-AQP4 autoantibody of human body.The present invention is using the AQP4- cell membrane complexes extracted as detection material, the intrinsic protein amount for causing background coloration can be lowered, relatively detection sensitivity and specificity are further increased using the method that cell is the Immunofluorescence test that detection material carries out at present, it is more easier testing result interpretation clear, simply and rapidly can be used to detect patient's AQP4 autoantibody.
Description
Technical field
The invention belongs to biomedicine field, it is related to a kind of anti-AQP4 autoantibody detection material of human body and its preparation side
Method, detection material obtained can be used in detecting the anti-AQP4 autoantibody of human body.
Background technique
Important blood serum designated object of the human body autoantibody as autoimmune disease, quickly detection is for autoimmunity
Diagnosis, remedy measures and the prognosis of property disease have important application value.The sensitivity and specificity detected with autoantibody
It improves, the diagnostic criteria of associated autoimmune disease also updates adjustment corresponding.
Neuromyelitis optica (neuromyelitis, NMO) is a kind of serious central nervous system demyelinating disease, about
Patient's aquaporin 4 (aquaporin, AQP4) antibody positive of 90% NMO and more than half.Aquaporin in 2004
The discovery of 4 antibody becomes independent disease for NMO and provides objective evidence, and the NMO diagnosis mark of correcting was included into 2015
It is quasi-.
Currently, the AQP4 autoantibody detection method in patients serum or cerebrospinal fluid includes the following categories: 1, using high table
Neural tissue slice up to the antigen carries out immunological experiment (indirect immunofluorescence, Indirect
Immunofluorescence Assay, IIF), to detect the autoantibody for AQP4.The method is due to neural tissue slice
Prepare more complex, differing greatly between batch, it is difficult to Quality Control；And to the more demanding of reviewer, need reviewer
There is nervous physiology abundant to gain knowledge, can just accurately identify the position in slice where positive signal and meaning, therefore realize quotient
The difficulty of product is larger.2, Immunofluorescence test or flow cytometry (cell-based are carried out using the cell of overexpression protection original
assay,CBA).But the major defect of such detection method is: (1) intracellular multiple protein may cause background coloration and ask
Topic.It in specific detection process, is compared in spite of idle running control cell, when external source antigen presentation amount is lower, part is detected
As a result still it is not easy clear interpretation.(2) operating process is complicated, and whether exact operations directly affect testing result to each step, this is very
The experience for relying on monitoring personnel, when being additionally carried out immunofluorescence or flow cytometry tests, needs specific apparatus, such as fluorescence microscopy
Mirror or flow cytometer.3, enzyme linked immunosorbent assay (ELISA) is carried out using recombinant antigen protein.AQP4 is as memebrane protein, just
The space conformation structure that true cross-film is formed is most important to the identification of autoantibody, during the expression of recombinant protein often because
It is incorrect to fold translation, the conception of mistake is formed, the specificity of detection is influenced.In addition, recombinant protein especially memebrane protein
Isolate and purify that work is relatively time consuming, effort.In addition there are the methods of several detection AQP4 autoantibodies, no longer enumerate herein.
Currently, IIF and CBA method is the common detection methods of anti-AQP4 autoantibody.IIF method is compared with CBA method sensibility and spy
It is anisotropic relatively low, thus it is speculated that may be because there are the differences between kind to cause for its reaction substrate.And CBA method stablizes height by building
The cell strain of people AQP4 is expressed as substrate, the difference between kind is on the one hand avoided, improves sensibility and the spy of the method
The opposite sex, the acquisition on the other hand detecting material are also easy relatively.
Summary of the invention
The purpose of the present invention is to provide anti-AQP4 autoantibody detection material of a kind of human body and preparation method thereof, the detections
Material can further decrease nonspecific signals, make to examine under the premise of based on cell detection method high sensitivity with specificity
It surveys result interpretation to be more easier to define, simply and rapidly can be used to detect patient's AQP4 autoantibody.
In order to achieve the above objectives, the technical solution adopted by the present invention are as follows:
A kind of preparation method of the anti-AQP4 autoantibody detection material of human body, comprising the following steps:
1) the AQP4 overall length target gene for obtaining M1, M23 hypotype, is distinguished target gene by pCI-neo plasmid vector
It is transfected into HEK293 cell, constructs HEK293/pCI-neo-M1-AQP4 cell and the expression of expression M1 hypotype AQP4 gene
The HEK293/pCI-neo-M23-AQP4 cell of M23 hypotype AQP4 gene；
2) AQP4- of HEK293/pCI-neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell is extracted
Cell membrane complexes；
3) the AQP4- cell membrane complexes of extraction are solidificated on carrier, obtain the anti-AQP4 autoantibody detection material of human body
Material.
The step 1) specifically includes the following steps:
1.1) the AQP4 overall length target gene of M1, M23 hypotype is obtained by artificial synthesized or PCR method, and in purpose base
Because both ends add NotI/NheI restriction enzyme site；
1.2) two kinds of target gene with restriction enzyme site are inserted into respectively in pCI-neo plasmid vector, insertion point is
NotI/NheI obtains two kinds of plasmids for having target gene, is respectively designated as pCI-neo-M1-AQP4 and pCI-neo-M23-
AQP4；
1.3) pCI-neo-M1-AQP4 plasmid and pCI-neo-M23-AQP4 plasmid are taken respectively, are transfected by PEI transfection reagent
Method transfects cultured HEK293 cell, obtains the HEK293/pCI-neo-M1-AQP4 cell of expression M1 hypotype AQP4 gene
With the HEK293/pCI-neo-M23-AQP4 cell of expression M23 hypotype AQP4 gene.
The specific steps of the step 2) are as follows: HEK293/pCI-neo-M1-AQP4 cell is removed by centrifugation respectively first
With the nucleus of HEK293/pCI-neo-M23-AQP4 cell, detergent is then added, 4 DEG C act on 30~60 minutes, then are centrifuged
Undissolved part is removed, supernatant is soluble AQP4- cell membrane complexes；Wherein detergent is 5~20mmol/L's
The Triton X-100 that CHAPS or volume fraction are 0.5~1%.
The specific steps of the step 2) are as follows: first pass through physical grinding, ultrasound or low temperature freeze thawing makes HEK293/pCI- respectively
The cellular membrane disruption of neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell discharges cell cytosol content,
Be then centrifuged for, abandon supernatant plasmosin, be added hypertonic solution into obtained precipitating, 4 DEG C act on 15~30 minutes, again from
The heart, abandons supernatant karyon albumen, and finally obtained precipitating is the AQP4- cell membrane complexes of insolubility.
The hypertonic solution is by Tris-HCl, NaCl, MgCl2It is formulated with EDTA, Tris-HCl in hypertonic solution
Concentration is that the concentration of 20mmol/L, NaCl are 300mmol/L, MgCl2Concentration be 2mmol/L, EDTA concentration be 2~
5mmol/L, the pH=8 of hypertonic solution.
The specific steps of the step 2) are as follows: first pass through physical grinding, ultrasound or low temperature freeze thawing makes HEK293/pCI- respectively
The cellular membrane disruption of neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell discharges cell cytosol content,
It is then centrifuged for, abandons supernatant plasmosin, Dextran-PEG-Na is added into obtained precipitating3PO4Liquid two-phase mixed liquor, then
Secondary centrifugation, is then allowed to stand, and forms two liquid phases, contains AQP4- cell membrane complexes in the liquid phase of top.
The Dextran-PEG-Na3PO4Liquid two-phase mixed liquor is by Dextran, PEG and Na3PO4It is formulated,
Dextran-PEG-Na3PO4It is 1.03g/mL that the volume fraction of Dextran, which is the concentration of 20%, PEG, in liquid two-phase mixed liquor,
Na3PO4Concentration be 0.2mol/L, Dextran-PEG-Na3PO4The pH=6.5 of liquid two-phase mixed liquor.
The carrier is nitrocellulose filter, pvdf membrane, nylon membrane, the slide with protein adsorption ability, plastic material
Tissue Culture Dish or culture plate.
The specific steps of the step 3) are as follows: dilute AQP4- cell membrane complexes with 1 × TBS buffer, be configured to
The dilution of AQP4- cell membrane complexes, the concentration of AQP4 is 0.1~1mg/mL in the dilution of AQP4- cell membrane complexes,
Then the dilution of AQP4- cell membrane complexes is pressed into round or linear trace on carrier with stroke film instrument, is then placed in 37 DEG C
Drying in oven reuses fixer and fixes 10~20 minutes, then washes away fixer with PBS buffer solution, finally with quality point
Number was closed 16~20 hours for 1% BSA confining liquid in closing 1 hour or 4 DEG C under room temperature, is drained confining liquid and is steamed with double
Water cleans up, and is dried at 20~28 DEG C to get to the anti-AQP4 autoantibody detection material of human body, is sealed in -20 DEG C
For use；It is the ethyl alcohol that 4% paraformaldehyde, ice methanol or volume fraction are 95% that wherein fixer, which is mass fraction,.
The anti-AQP4 autoantibody inspection of human body made from the preparation method of the anti-AQP4 autoantibody detection material of the human body
It measures and monitor the growth of standing timber material, which is the AQP4- cell membrane complexes being solidificated on carrier, and wherein AQP4- cell membrane complexes are by table
Up to the HEK293/pCI-neo-M1-AQP4 cell of M1 hypotype AQP4 gene and the HEK293/ of expression M23 hypotype AQP4 gene
PCI-neo-M23-AQP4 cell extraction obtains.
The main component of AQP4- cell membrane complexes is with bioactivity, keeps the HEK293/ of its original space conformation
The cell membrane of pCI-neo-M1-AQP4 and HEK293/pCI-neo-M23-AQP4 cell, while may be comprising some thin in separation
The substances such as indivisible organelle during after birth, but wherein play the role of confrontation AQP4 autoantibody detection is
The cell membrane of HEK293/pCI-neo-M1-AQP4 and HEK293/pCI-neo-M23-AQP4 cell.
Compared with the existing technology, the invention has the benefit that
The preparation method of the anti-AQP4 autoantibody detection material of human body provided by the invention, first obtains M1, M23 hypotype
Target gene is transfected into HEK293 cell by pCI-neo plasmid vector, constructs expression by AQP4 overall length target gene
The HEK293/pCI-neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell of M1, M23 hypotype AQP4 gene；
The AQP4- cell membrane in HEK293/pCI-neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell is extracted again
Compound；Finally the AQP4- cell membrane complexes of extraction are solidificated on carrier and are detected to get to the anti-AQP4 autoantibody of human body
Material.The present invention using the AQP4- cell membrane complexes extracted as the detection material for detecting the anti-AQP4 autoantibody of human body,
The intrinsic protein amount for causing background coloration can be lowered, more current CBA method is the immunofluorescence for detecting material and carrying out using cell
The method of detection further increases detection sensitivity and specificity, can further decrease nonspecific signals, make testing result
Interpretation is more easier clear.And the application method of the anti-AQP4 autoantibody detection material of human body prepared by the present invention is also simpler
It is single, reviewer is required low, entire testing process expends that the time is short, and required instrument is simple, can simply and rapidly be used to examine
Survey patient AQP4 autoantibody.
The anti-AQP4 autoantibody of human body produced by the present invention detects material, is that the AQP4 cell membrane of space conformation will be kept to answer
It closes object and is solidificated in and obtained on carrier, it, can be further based on cell detection method high sensitivity and under the premise of specificity
Nonspecific signals are reduced, is more easier testing result interpretation clear, simply and rapidly can be used to detect patient AQP4 itself
Antibody.
Further, in the preparation method of the anti-AQP4 autoantibody detection material of human body provided by the invention, key point
It is to obtain the AQP4 cell membrane complexes for keeping space conformation.The entire mistake of AQP4- cell membrane complexes is extracted in the present invention
Cheng Zhong is able to maintain membrane protein configuration and is not destroyed, and loses Membrane protein antigen not.Abandon cell cytosol and karyon at
Point, the AQP4- cell membrane complexes of extraction can lower the intrinsic protein amount for causing background coloration, increase as detection material
Detection sensitivity and specificity.In addition the present invention in AQP4- cell membrane complexes simple and convenient extraction, do not need special instrument
Device relatively purifies the cost of memebrane protein and technical requirements substantially reduces.
Detailed description of the invention
Fig. 1 is the schematic diagram that the anti-AQP4 autoantibody of human body prepared by the present invention detects material, and wherein a-quadrant is coated with M23-
AQP4 cell membrane complexes；B area is coated with pCI-neo cell membrane complexes.
Fig. 2 is that the anti-AQP4 autoantibody of human body prepared by the present invention detects in material tests NMO patient and normal human serum
Anti- AQP4 Antibody Results, it is known NMO patients serum that wherein a, which is detection serum, and b is that detection serum is known normal blood
Clearly.
Specific embodiment
Below with reference to specific embodiment, the present invention is described in further detail.
The preparation method of the anti-AQP4 autoantibody detection material of human body provided by the invention specifically includes the following steps:
One, AQP4 overall length target gene that is artificial synthesized or being obtained by PCR method, building stabilization or transient expression M1, M23
HEK293/pCI-neo-M1-AQP4, HEK293/pCI-neo-M23-AQP4 cell of hypotype, and the HEK293/pCI-neo that dallies
Cell is as a control group.The specific steps of which are as follows:
1. plasmid construction
1.1 target gene obtain: the AQP4 overall length purpose base of M1, M23 hypotype is obtained by artificial synthesized or PCR method
Cause, both ends add the restriction enzyme site of NotI/NheI.
Obtain two kinds of target gene are inserted into carrier pCI-neo plasmid by 1.2 respectively, and insertion point NotI/NheI will
Two kinds of obtained plasmids are respectively designated as pCI-neo-M1-AQP4 and pCI-neo-M23-AQP4, and correct rear extraction plasmid is sequenced
Carry out subsequent experimental.The specific method is as follows:
A. the glycerol strain of pCI-neo plasmid is taken to be inoculated in the 3mL of ammonia benzyl resistance, LB liquid medium sets 37 DEG C of constant temperature
Incubator, 220r/min shake bacterium overnight.
B. second day draws 500 μ L of bacterium solution and saves strain, and the remaining small extraction reagent kit of 2.5mL bacterium solution plasmid is extracted, surveyed dense
Degree.
C.pCI-neo carrier digestion: 40 μ L digestion systems, 2 μ g carriers, NotI, each 1 μ L, 10x digestion Buffer of NheI enzyme
4 μ L, ddH2O polishing is to 40 μ L, 37 DEG C of insulating box digestion 2h.
D. digestion products recycle, and 0.8% agarose gel electrophoresis separates digestion products, illustrate according to gel reclaims kit
Book carries out carrier segments recycling.
E. target gene is connect with carrier segments: 20 μ L linked systems, 50ng pCI-neo carrier, 150ng M23-
AQP4, T4 ligase 1 μ L, ddH2O polishing is to 20 μ L, and 4 DEG C of connections are overnight.
F. by the pCI-neo-M23-AQP4 plasmid equipped with M23-AQP4 genetic fragment or equipped with M1-AQP4 genetic fragment
PCI-neo-M1-AQP4 plasmid is transformed into bacillus coli DH 5 alpha, applies ammonia benzyl solid LB culture plate, 37 DEG C overnight, and second day is chosen
5 bacterial strains are taken, the LB liquid medium of inoculation and ammonia benzyl resistance, 37 DEG C are incubated overnight.Next day, each pipe draw 500 μ L bacterium solutions ,-
20 DEG C of preservations, remaining bacterium solution plasmid is small to be mentioned, and digestion identifies that correct bacterial strain send sequencing to identify again.Correct bacterial strain is identified in sequencing
Leave and take strain, -80 DEG C of preservations.
G. sequencing correctly carries out plasmid and mentions greatly with target gene strain and the expansion culture of carrier strain, side concentration.
2.AQP4 expresses 293T cell construction
2.1HEK293 cell culture, DMEM high glucose medium and FBS are configured to 10%FBS-DMEM high sugar in 9:1 ratio
Culture medium is passed on by 1:3 to cell fusion to 90%, continues subculture to the 3rd generation, cover with to the 3rd generation cell to 80-90%
When, cell suspension inoculation is made in 10cm Tissue Culture Dish with complete medium in 0.05% trypsin digestion, is inoculated with 1.5x106
A cell is added complete medium to 10mL, sets 37 DEG C, 5%CO2Cell incubator in cultivate.
2.2 is long to culture dish floor space 70-80% to HEK293 cell in 10cm culture dish, replaces fresh culture and continues
4h is cultivated, is transfected by PEI transfection reagent transfection method, takes pCI-neo-M1-AQP4 plasmid or pCI-neo-M23-AQP4
Plasmid 30 μ g, PEI are 45 μ g.Fresh medium is replaced after transfection after 6h, collects cell after transfecting 72h, is stablized or instantaneous
Express HEK293/pCI-neo-M1-AQP4, HEK293/pCI-neo-M23-AQP4 cell of M1, M23 hypotype.
2.3, by pCI-neo plasmid transfection HEK293 cell, obtain HEK293/pCI-neo cell and compare.
Two, the acquisition of AQP4- cell membrane complexes.
It collects HEK293/pCI-neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell height expresses purpose
AQP4 albumen and the HEK293/pCI-neo cell of idle running extract AQP4- cell membrane complexes, and it is compound to obtain AQP4- cell membrane
Object includes but is not limited to following several method:
A: soluble AQP4- cell membrane complexes are obtained with de-sludging agent method.5-20mmol/ can be used in detergent herein
L CHAPS, 0.5-1%Triton X-100 etc..Cell low-speed centrifugal is removed into core first, detergent cold service is then added
30-60 minutes, then undissolved part is removed by low-speed centrifugal, supernatant is soluble AQP4- cell membrane complexes.
B: with the cell membrane extracting method for gradually removing nucleus and endochylema, the AQP4- cell membrane for obtaining insolubility is multiple
Close object.Cellular membrane disruption is made by physical grinding, ultrasound or low temperature freeze thawing first, discharges cell cytosol content.High speed centrifugation
Supernatant plasmosin is abandoned, hypertonic solution is added in precipitating: 20mmol/L Tris-HCl, 300mmol/L NaCl, 2mmol/L
MgCl2, 2-5mmol/L EDTA, pH 8, cold service 15-30 minutes, 12000-15000rpm, 10 minutes, abandoning supernatant karyon
Albumen, precipitating are the AQP4- cell membrane complexes of insolubility.
C: AQP4- cell membrane complexes are obtained with cell membrane liquid two-phase centrifugal separation.Smudge cells, remove endochylema and
Nucleoprotein refers to b method, and some organelles are also contained in the precipitating that high speed centrifugation obtains herein, Dextran- is added in precipitating
PEG-Na3PO4Liquid two-phase mixed liquor (20%Dextran, 103g PEG, 0.2mol/L Na3PO4, pH 6.5), 2000-
3000g, 4 DEG C, 10 minutes.It slightly stands, forms two liquid phases, mainly contain cell membrane fragment in the liquid phase of top.
For obtaining M23-AQP4- cell membrane complexes using b method, below specific steps:
After transfecting 72h, HEK293/pCI-neo-M23-AQP4 cell is collected, cell, glass is resuspended in 500 μ L hypotonic solutions
Homogenizer is homogenized 50 times, makes cellular membrane disruption, discharges cell cytosol content.12000rpm, 4 DEG C of centrifugation 10min abandon supernatant born of the same parents
Albumen is starched, hypertonic solution is added in precipitating: 20mmol/L Tris-HCl, 300mmol/L NaCl, 2mmol/L MgCl2,
2mmol/L EDTA, pH 8, cold service 30min, 12000rpm, 4 DEG C, 10min abandon supernatant karyon albumen, precipitate as thin
Mixing is sufficiently resuspended in after birth compound, 1xTBS.
Three, solidification AQP4- cell membrane complexes detect material as the anti-AQP4 autoantibody of human body.
Used solidified carrier can be nitrocellulose filter, pvdf membrane, nylon membrane, and the glass with protein adsorption ability
Piece, the Tissue Culture Dish of plastic material, culture plate etc..By adjusting the coated AQP4- cell membrane complexes quantity of unit area,
Uniform the AQP4 antigen protein amount (or density) of experimental group and negative control group.With point film instrument, film instrument is drawn by AQP4- cell
On carrier, film is placed in 37 DEG C of incubators 30-60 minutes by round or linear trace for the dilution of membrane complex.Use fixation
Liquid is such as: 4% paraformaldehyde, ice methanol, and 95% dehydrated alcohol etc. is 10-20 minutes fixed, with cleaning solution washes clean fixer.Envelope
Liquid is closed in closing closing in 1 hour or 4 DEG C 16-20 hours under room temperature, confining liquid is drained and is cleaned with distilled water, at 20-28 DEG C
Under the conditions of dry, be sealed in -20 DEG C.
For solidifying M23-AQP4- cell membrane complexes, the specific steps are as follows:
M23-AQP4 antigen protein concentration in the M23-AQP4- cell membrane complexes extracted is measured with BCA, with 1xTBS tune
Its whole ultimate density is to 1mg/mL.It is with point film instrument that M23-AQP4 cell membrane complexes dilution and pCI-neo cell membrane is compound
Object dilution by round trace on nitrocellulose membrane, slightly dry, and film is placed in 37 DEG C of incubators 30 minutes by room temperature.It is complete to film
10 minutes are fixed using 4% paraformaldehyde after absolutely dry, PBS is washed film 3 times, 3 minutes/time.1%BSA confining liquid is in room temperature item
It is closed 1 hour under part, distilled water cleans 3 times, 3 minutes/time.It dries under the conditions of 20-28 DEG C, is sealed in -20 DEG C.
The anti-AQP4 autoantibody detection material of human body prepared by the present invention can be used for color developing detection.It is coated with correct space structure
The M1-AQP4- cell membrane complexes of elephant or the detection material of M23-AQP4- cell membrane complexes, in combination with needle in dilute sample
To the autoantibody IgG of AQP4 linear epitope or comformational epitope, the antibody on detection material is integrated to by enzyme mark anti-human igg secondary antibody
Identification carrys out in judgement sample whether there is the autoantibody of anti-AQP4 finally by chromogenic reaction.
Specific detecting step is as follows:
A) the anti-AQP4 autoantibody detection material of human body prepared by the present invention is placed in 12 orifice plates, is coated with the one of AQP4 antigen
Up.
B) serum is incubated for: test sample adds in hole after diluting by 1:500, the hole 1mL/.12 orifice plates are placed in horizontal shaker
(frequency is about 30 beats/min) is incubated at room temperature 40 minutes.
C) wash: the serum Incubating Solution in removal hole is added cleaning solution, the hole 1mL/, be placed in shaking table (frequency is about 30 times/
Minute), room temperature 3-5 minutes, discard the cleaning solution in hole.Repeated washing totally 3 times.
D) secondary antibody is incubated for: the cleaning solution in removal hole, and the diluted AP of 1:100 is added and marks goat anti-human igg antibody, 1mL/
Hole.It is placed in shaking table (frequency is about 30 beats/min), is incubated at room temperature 30 minutes.
E) wash: the secondary antibody Incubating Solution in removal hole is added cleaning solution, the hole 1mL/, be placed in shaking table (frequency is about 30 times/
Minute), room temperature 3-5 minutes, discard cleaning solution in hole.Repeated washing totally 3 times.
F) it develops the color.After removing the cleaning solution in hole, the dilution (substrate: reaction buffer=1:49) of substrate is added,
The hole 1mL/.Room temperature is protected from light standing 2-5 minutes, can check every 1 minute primary.
G) color development stopping.The substrate dilution in hole is discarded, and rinses detection material of the invention 1-2 times with distilled water,
It is drawn off drying or 37 DEG C -45 DEG C dries, analyze result.
Testing result interpretation is as follows:
Positive findings interpretation: the AQP4 antigen coat area of the anti-AQP4 autoantibody detection material of human body prepared by the present invention is in
Now apparent color spot, shape is approximate circle, light slate gray to deep blue-black, and color is deep compared with its neighboring area and negative control area
(as shown in Figure 2 a).
Negative findings interpretation: the AQP4 antigen coat area face of the anti-AQP4 autoantibody detection material of human body prepared by the present invention
Color is shallower than negative control area, or be equal to negative control area (as shown in Figure 2 b) etc., it is determined as negative findings.
Fig. 1 is the schematic diagram that the anti-AQP4 autoantibody of human body prepared by the present invention detects material, and wherein a-quadrant is coated with M23-
AQP4 cell membrane complexes；B area is coated with pCI-neo cell membrane complexes, as negative control.
Fig. 2 is to detect material tests NMO patient and normal human serum with the anti-AQP4 autoantibody of human body prepared by the present invention
In anti-AQP4 Antibody Results, it is known NMO patients serum that wherein Fig. 2 a, which is detection serum, through chromogenic reaction, a-quadrant AQP4-
Cell membrane complexes are coated with area and more apparent color occur compared with B area negative control group, and such situation regards as detection serum
In contain anti-AQP4 antibody；Fig. 2 b is that detection serum is known normal serum, and through chromogenic reaction, a-quadrant AQP4- cell membrane is multiple
It closes object coating area and does not occur more apparent color compared with B area negative control group, the two is presented identical color, such situation,
It regards as in detection serum without anti-AQP4 antibody.
The above is only presently preferred embodiments of the present invention, is not intended to limit the invention in any way, it is all according to the present invention
Technical spirit any simple modification, change and equivalent structure transformation to the above embodiments, still fall within skill of the present invention
In the protection scope of art scheme.
Claims (5)
1. a kind of preparation method of the anti-AQP4 autoantibody detection material of human body, which comprises the following steps:
1) the AQP4 overall length target gene for obtaining M1, M23 hypotype, is transfected target gene by pCI-neo plasmid vector respectively
Enter in HEK293 cell, constructs the HEK293/pCI-neo-M1-AQP4 cell and expression M23 of expression M1 hypotype AQP4 gene
The HEK293/pCI-neo-M23-AQP4 cell of hypotype AQP4 gene；
2) the AQP4- cell of HEK293/pCI-neo-M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell is extracted
Membrane complex；
3) the AQP4- cell membrane complexes of extraction are solidificated on carrier, obtain the anti-AQP4 autoantibody detection material of human body；
The specific steps of step 2) are as follows: first by centrifugation respectively removal HEK293/pCI-neo-M1-AQP4 cell and
Then detergent is added in the nucleus of HEK293/pCI-neo-M23-AQP4 cell, 4 DEG C act on 30~60 minutes, then are centrifuged
Except undissolved part, supernatant is soluble AQP4- cell membrane complexes；Wherein detergent is the CHAPS of 5~20mmol/L
Or the Triton X-100 that volume fraction is 0.5~1%；
Or the specific steps of step 2) are as follows: first pass through physical grinding, ultrasound or low temperature freeze thawing makes HEK293/pCI-neo- respectively
The cellular membrane disruption of M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell discharges cell cytosol content, then
Supernatant plasmosin is abandoned in centrifugation, and hypertonic solution is added into obtained precipitating, and 4 DEG C act on 15~30 minutes, are centrifuged again, is abandoned
Supernatant karyon albumen, finally obtained precipitating are the AQP4- cell membrane complexes of insolubility；The hypertonic solution by
Tris-HCl、NaCl、MgCl2It is formulated with EDTA, the concentration of Tris-HCl is the dense of 20mmol/L, NaCl in hypertonic solution
Degree is 300mmol/L, MgCl2Concentration be the concentration of 2mmol/L, EDTA be 2~5mmol/L, the pH=8 of hypertonic solution；
Or the specific steps of step 2) are as follows: first pass through physical grinding, ultrasound or low temperature freeze thawing makes HEK293/pCI-neo- respectively
The cellular membrane disruption of M1-AQP4 cell and HEK293/pCI-neo-M23-AQP4 cell discharges cell cytosol content, then
Centrifugation abandons supernatant plasmosin, Dextran-PEG-Na is added into obtained precipitating3PO4Liquid two-phase mixed liquor, again from
The heart is then allowed to stand, and is formed two liquid phases, is contained AQP4- cell membrane complexes in the liquid phase of top；The Dextran-
PEG-Na3PO4Liquid two-phase mixed liquor is by Dextran, PEG and Na3PO4It is formulated, Dextran-PEG-Na3PO4Liquid two
The concentration that the volume fraction for mixing Dextran in liquid is 20%, PEG is 1.03g/mL, Na3PO4Concentration be 0.2mol/L,
Dextran-PEG-Na3PO4The pH=6.5 of liquid two-phase mixed liquor.
2. the preparation method of the anti-AQP4 autoantibody detection material of human body according to claim 1, which is characterized in that described
Step 1) specifically includes the following steps:
1.1) the AQP4 overall length target gene of M1, M23 hypotype is obtained by artificial synthesized or PCR method, and in target gene two
End adds NotI/NheI restriction enzyme site；
1.2) two kinds of target gene with restriction enzyme site are inserted into respectively in pCI-neo plasmid vector, insertion point NotI/
NheI obtains two kinds of plasmids for having target gene, is respectively designated as pCI-neo-M1-AQP4 and pCI-neo-M23-AQP4；
1.3) pCI-neo-M1-AQP4 plasmid and pCI-neo-M23-AQP4 plasmid are taken respectively, by PEI transfection reagent transfection method
Cultured HEK293 cell is transfected, the HEK293/pCI-neo-M1-AQP4 cell and table of expression M1 hypotype AQP4 gene are obtained
Up to the HEK293/pCI-neo-M23-AQP4 cell of M23 hypotype AQP4 gene.
3. the preparation method of the anti-AQP4 autoantibody detection material of human body according to claim 1, which is characterized in that described
Carrier is the Tissue Culture Dish of nitrocellulose filter, pvdf membrane, nylon membrane, the slide with protein adsorption ability, plastic material
Or culture plate.
4. the preparation method of the anti-AQP4 autoantibody detection material of human body according to claim 1, which is characterized in that described
The specific steps of step 3) are as follows: dilute AQP4- cell membrane complexes with 1 × TBS buffer, it is compound to be configured to AQP4- cell membrane
The dilution of object, the concentration of AQP4 is 0.1~1mg/mL in the dilution of AQP4- cell membrane complexes, then with draw film instrument will
The dilution of AQP4- cell membrane complexes is then placed in 37 DEG C of drying in oven on carrier by round or linear trace, then makes
10~20 minutes are fixed with fixer, then washes away fixer with PBS buffer solution, is finally closed with the BSA that mass fraction is 1%
Liquid drains confining liquid and is cleaned up with distilled water, 20 in closing closing in 1 hour or 4 DEG C 16~20 hours under room temperature
It is dried at~28 DEG C to get to the anti-AQP4 autoantibody detection material of human body, is sealed in -20 DEG C stand-by；Wherein fixer
It is the ethyl alcohol that 4% paraformaldehyde, ice methanol or volume fraction are 95% for mass fraction.
5. people made from the preparation method of the anti-AQP4 autoantibody detection material of human body described in any one of claim 1-4
The anti-AQP4 autoantibody of body detects material, which is characterized in that the detection material is that the AQP4- cell membrane that is solidificated on carrier is compound
Object, wherein AQP4- cell membrane complexes by express M1 hypotype AQP4 gene HEK293/pCI-neo-M1-AQP4 cell and table
HEK293/pCI-neo-M23-AQP4 cell extraction up to M23 hypotype AQP4 gene obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710175642.9A CN107022548B (en) | 2017-03-22 | 2017-03-22 | Anti- AQP4 autoantibody detection material of a kind of human body and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710175642.9A CN107022548B (en) | 2017-03-22 | 2017-03-22 | Anti- AQP4 autoantibody detection material of a kind of human body and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107022548A CN107022548A (en) | 2017-08-08 |
| CN107022548B true CN107022548B (en) | 2019-02-01 |
Family
ID=59526210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710175642.9A Active CN107022548B (en) | 2017-03-22 | 2017-03-22 | Anti- AQP4 autoantibody detection material of a kind of human body and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107022548B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109425603A (en) * | 2017-08-23 | 2019-03-05 | 迪亚莱博（张家港）生物科技有限公司 | A kind of chemoluminescence method quickly detects the kit of perilipin 2 |
| CN110606881A (en) * | 2019-08-12 | 2019-12-24 | 陕西脉元生物科技有限公司 | Detection material for anti-MOG autoantibody in human body fluid, preparation method and application |
| CN110606888B (en) * | 2019-08-12 | 2021-08-31 | 陕西脉元生物科技有限公司 | Detection material for anti-GABABR autoantibody in human body fluid, preparation method and application |
| CN110606885B (en) * | 2019-08-12 | 2021-03-23 | 陕西脉元生物科技有限公司 | Detection material for anti-AMPA 1 autoantibody in human body fluid, preparation method and application |
| CN110606887A (en) * | 2019-08-12 | 2019-12-24 | 陕西脉元生物科技有限公司 | Detection material for anti-NMDAR autoantibody in human body fluid, preparation method and application |
| CN110606886B (en) * | 2019-08-12 | 2021-06-01 | 陕西脉元生物科技有限公司 | Detection material for anti-CASPR 2 autoantibody in human body fluid, preparation method and application |
| CN110618264A (en) * | 2019-09-10 | 2019-12-27 | 南方医科大学 | Method for detecting anti-AQP 4 antibody based on quantum dot polystyrene microspheres |
| CN112691235A (en) * | 2019-10-23 | 2021-04-23 | 易成刚 | Preparation and application of fat-derived acellular matrix mainly prepared from human and pig by physical method |
| CN111471656A (en) * | 2020-04-30 | 2020-07-31 | 北京和合医学诊断技术股份有限公司 | Stable transfer cell strain for detecting NMO-IgG and construction method thereof |
| CN115232795B (en) * | 2021-07-22 | 2023-09-19 | 北京和合医学诊断技术股份有限公司 | Cell strain for stably expressing AQP4-M23 protein, construction method and application thereof |
| CN113740531B (en) * | 2021-09-01 | 2023-02-03 | 陕西脉元生物科技有限公司 | Cell for reducing fluorescence nonspecific color development, detection product based on cell and application of cell in detecting autoantibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103937836A (en) * | 2014-04-04 | 2014-07-23 | 天津医科大学总医院 | Detection method of aquaporin-4 autoantibody, fusion expression virus vector and application thereof |
| WO2016159960A1 (en) * | 2015-03-30 | 2016-10-06 | Hycor Biomedical, Inc. | Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases |
| CN106318974A (en) * | 2016-08-29 | 2017-01-11 | 南方医科大学南方医院 | Cell immobilization technology and AQP4 antibody detection kit prepared through same |
-
2017
- 2017-03-22 CN CN201710175642.9A patent/CN107022548B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107022548A (en) | 2017-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107022548B (en) | Anti- AQP4 autoantibody detection material of a kind of human body and preparation method thereof | |
| WO2021179371A1 (en) | Novel coronavirus n-s dominant epitope fusion protein, preparation method therefor and application thereof, expression protein, microorganism, application thereof and kit | |
| CN105954521B (en) | MTB (Mycobacterium Tuberculosis) infection diagnosis kit | |
| CN110568178B (en) | A Zika virus NS1 antigen and its application in the preparation of fluorescent immunochromatographic reagents | |
| CN109180519B (en) | A kind of olaquindox metabolite antigen, antibody and enzyme-linked immunosorbent assay kit and detection method | |
| CN104345154B (en) | A kind of double-antibody sandwich test kit detecting many tumors relevant " the box-like mark of polypeptide-protein groups " | |
| CN105445462A (en) | Enzyme linked immunosorbent assay kit for specific quantitative detection of foot and mouth disease O type Guangxi strain antigen and application thereof | |
| CN108931513B (en) | Method and kit for in vitro detection of MUSK-Ab and LRP4-Ab | |
| CN110174519B (en) | Confluent-detection type erythrocyte blood type irregular antibody detection kit based on solid-phase agglutination technology and preparation method thereof | |
| CN109810191B (en) | A kind of anti-sheep skeletal muscle troponin I monoclonal antibody and its application | |
| PT1761785E (en) | Method of diagnosing lawsonia intracellularis | |
| CN101738474B (en) | Combined test reagent card for cytomegalovirus and rubella virus | |
| US9632086B2 (en) | Method and kit for determining-antibody sensitivity and clone cell strain | |
| CN117447602B (en) | Antibodies to porcine IgM and uses thereof | |
| CN102368068B (en) | Kit for detecting chlamydia pneumoniae IgM antibody | |
| CN117384295A (en) | Mouse anti-goose IgY monoclonal antibody and application thereof | |
| CN106520702A (en) | A kind of hybridoma cell line, its secreted monoclonal antibody and application | |
| CN108239651A (en) | A kind of recombination fusion alkaline phosphatase-allergen protein and its preparation method and application | |
| CN115873839A (en) | Detection material for detecting MOG antibody titer and preparation method thereof | |
| CN104672331A (en) | Preparation method of thymidine kinase 1 antibody and application of thymidine kinase 1 antibody in proliferation of ureaplasma urealyticum | |
| CN109975541A (en) | A kind of detection card and preparation method thereof of quick detection canine distemper virus antigen | |
| LU500582B1 (en) | Muscovy Duck Parvovirus POCT Test Strip, Preparation Method Therefor and Application Thereof | |
| CN102605105B (en) | Diagnostic kit used for identifying reverse transcription-composite nested polymerase chain reaction of swine fever vaccine strains and pandemic strains and detection method | |
| CN101738472A (en) | Biological chip for synchronously detecting typhoid and paratyphoid and preparation method thereof | |
| CN107202882B (en) | Purposes of the Rv0440 albumen in diagnosis latency/active tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |